Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae
© 2023, Aguinagalde Salazar et al..
Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and an important cause of childhood mortality. Despite the introduction of successful vaccines, the global spread of both non-vaccine serotypes and antibiotic-resistant strains reinforces the development of alternative therapies against this pathogen. One possible route is the development of monoclonal antibodies (mAbs) that induce killing of bacteria via the immune system. Here, we investigate whether mAbs can be used to induce killing of pneumococcal serotypes for which the current vaccines show unsuccessful protection. Our study demonstrates that when human mAbs against pneumococcal capsule polysaccharides (CPS) have a poor capacity to induce complement activation, a critical process for immune protection against pneumococci, their activity can be strongly improved by hexamerization-enhancing mutations. Our data indicate that anti-capsular antibodies may have a low capacity to form higher-order oligomers (IgG hexamers) that are needed to recruit complement component C1. Indeed, specific point mutations in the IgG-Fc domain that strengthen hexamerization strongly enhance C1 recruitment and downstream complement activation on encapsulated pneumococci. Specifically, hexamerization-enhancing mutations E430G or E345K in CPS6-IgG strongly potentiate complement activation on S. pneumoniae strains that express capsular serotype 6 (CPS6), and the highly invasive serotype 19A strain. Furthermore, these mutations improve complement activation via mAbs recognizing CPS3 and CPS8 strains. Importantly, hexamer-enhancing mutations enable mAbs to induce strong opsonophagocytic killing by human neutrophils. Finally, passive immunization with CPS6-IgG1-E345K protected mice from developing severe pneumonia. Altogether, this work provides an important proof of concept for future optimization of antibody therapies against encapsulated bacteria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
eLife - 12(2023) vom: 22. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aguinagalde Salazar, Leire [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Complement system |
|---|
| Anmerkungen: |
Date Completed 24.03.2023 Date Revised 24.03.2023 published: Electronic Dryad: 10.5061/dryad.s1rn8pkbt Citation Status MEDLINE |
|---|
| doi: |
10.7554/eLife.80669 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354523554 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354523554 | ||
| 003 | DE-627 | ||
| 005 | 20231226062416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.80669 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1181.xml |
| 035 | |a (DE-627)NLM354523554 | ||
| 035 | |a (NLM)36947116 | ||
| 035 | |a (PII)e80669 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aguinagalde Salazar, Leire |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2023 | ||
| 500 | |a Date Revised 24.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Dryad: 10.5061/dryad.s1rn8pkbt | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023, Aguinagalde Salazar et al. | ||
| 520 | |a Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and an important cause of childhood mortality. Despite the introduction of successful vaccines, the global spread of both non-vaccine serotypes and antibiotic-resistant strains reinforces the development of alternative therapies against this pathogen. One possible route is the development of monoclonal antibodies (mAbs) that induce killing of bacteria via the immune system. Here, we investigate whether mAbs can be used to induce killing of pneumococcal serotypes for which the current vaccines show unsuccessful protection. Our study demonstrates that when human mAbs against pneumococcal capsule polysaccharides (CPS) have a poor capacity to induce complement activation, a critical process for immune protection against pneumococci, their activity can be strongly improved by hexamerization-enhancing mutations. Our data indicate that anti-capsular antibodies may have a low capacity to form higher-order oligomers (IgG hexamers) that are needed to recruit complement component C1. Indeed, specific point mutations in the IgG-Fc domain that strengthen hexamerization strongly enhance C1 recruitment and downstream complement activation on encapsulated pneumococci. Specifically, hexamerization-enhancing mutations E430G or E345K in CPS6-IgG strongly potentiate complement activation on S. pneumoniae strains that express capsular serotype 6 (CPS6), and the highly invasive serotype 19A strain. Furthermore, these mutations improve complement activation via mAbs recognizing CPS3 and CPS8 strains. Importantly, hexamer-enhancing mutations enable mAbs to induce strong opsonophagocytic killing by human neutrophils. Finally, passive immunization with CPS6-IgG1-E345K protected mice from developing severe pneumonia. Altogether, this work provides an important proof of concept for future optimization of antibody therapies against encapsulated bacteria | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a S. pneumoniae | |
| 650 | 4 | |a complement system | |
| 650 | 4 | |a hexamer-enhancing mutations | |
| 650 | 4 | |a infectious disease | |
| 650 | 4 | |a microbiology | |
| 650 | 4 | |a monoclonal antibodies | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a den Boer, Maurits A |e verfasserin |4 aut | |
| 700 | 1 | |a Castenmiller, Suzanne M |e verfasserin |4 aut | |
| 700 | 1 | |a Zwarthoff, Seline A |e verfasserin |4 aut | |
| 700 | 1 | |a de Haas, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Aerts, Piet C |e verfasserin |4 aut | |
| 700 | 1 | |a Beurskens, Frank J |e verfasserin |4 aut | |
| 700 | 1 | |a Schuurman, Janine |e verfasserin |4 aut | |
| 700 | 1 | |a Heck, Albert J R |e verfasserin |4 aut | |
| 700 | 1 | |a van Kessel, Kok |e verfasserin |4 aut | |
| 700 | 1 | |a Rooijakkers, Suzan H M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t eLife |d 2012 |g 12(2023) vom: 22. März |w (DE-627)NLM221831460 |x 2050-084X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g day:22 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7554/eLife.80669 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |b 22 |c 03 | ||